Prabhudas Lilladher raised its target for Apollo Hospitals stock

Published on 10/09/2026 at 12:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 FY27 revenue reached INR 70.44 billion, up 21.00 percent year on year. Apollo Hospitals stock stands below the INR 10,000.00 target.

Key points in brief

Prabhudas Lilladher raised its Apollo Hospitals target to INR 10,000.00 from INR 9,350.00 on August 14, 2026.
Apollo Hospitals reported Q1 FY27 revenue of INR 70.44 billion, up 21.00 percent year on year.
NSE data showed INR 7,907.00 on October 9, 2026, up 3.15 percent versus the INR 7,666.00 prior close.
The broker cited hospital expansion, HealthCo restructuring and digital-health improvement, alongside execution risks.

Apollo Hospitals, INE437A01024, Illustration mit AI erstellt.

Apollo Hospitals (INE437A01024) traded at INR 7,907.00 on the NSE on October 9, 2026, up 3.15 percent from the INR 7,666.00 prior close. On August 14, 2026, DSIJ reported that Prabhudas Lilladher raised its target to INR 10,000.00 from INR 9,350.00 while retaining its Buy rating. The target revision followed Q1 FY27 results and the broker's assessment of Apollo HealthCo restructuring.

Three dated milestones shape the case

On May 20, 2026, Apollo Hospitals reported FY26 consolidated revenue of INR 25.23 billion, up 16.00 percent year on year, and recommended a final dividend of INR 10.00 per share, according to ALFA Finder. On June 24, 2026, shareholders and creditors considered the composite scheme of arrangement, with the restructuring aimed at separating selected digital-health and pharmacy activities.

On August 14, 2026, the broker target moved to INR 10,000.00. That sequence links the valuation case to both operating growth and the planned business reorganization, rather than to a single quarter alone.

What does the target change mean?

DSIJ said consolidated Q1 FY27 revenue rose 21.00 percent year on year to INR 70.44 billion. Adjusted profit after tax increased 34.00 percent to INR 5.81 billion, while EBITDA rose 28.00 percent to INR 10.92 billion and the EBITDA margin reached 15.50 percent.

The report also identified pressure points. New hospital units generated INR 380.00 million of losses in Q1 FY27, while digital operations still recorded cash losses of INR 100.00 million. Prabhudas Lilladher nevertheless estimated a 25.00 percent EBITDA compound annual growth rate for fiscal years 2026 through 2028 and cited a planned pharmacy entity exit EBITDA run rate of INR 16.50 billion to INR 17.50 billion by Q4 FY27.

Price stays below the revised target

The NSE quotation of INR 7,907.00 on October 9, 2026 stood 12.50 percent below the INR 9,026.00 midpoint between the reported 52-week range of INR 6,696.50 to INR 9,070.50. Market capitalization was INR 1.1 trillion as of October 7, 2026, while the stock was included in the BSE 100.

The distance between the NSE price and the revised target remains a valuation reference, not a forecast. Execution of new beds, regulatory approvals for the restructuring and the path to digital-health profitability are the measurable factors behind the broker's assessment.

Trading context for October 9

At INR 7,907.00, Apollo Hospitals was 12.82 percent below the revised INR 9,070.50 52-week high and 18.09 percent above the INR 6,696.50 low. The daily increase of 3.15 percent was measured against the NSE prior close of INR 7,666.00 on October 9, 2026.

Market context: Market report BSE Sensex.